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Abstract
Background: Immunocompromised individuals with chronic norovirus (NoV) infection and elderly patients are
hypothesized to be reservoirs where NoV might accumulate mutations and evolve into pandemic strains. Next
generation sequencing (NGS) methods can monitor the intra-host diversity of NoV and its evolution but low
abundance of viral RNA results in sub-optimal efficiency. In this study, we: 1) established a next generation
sequencing-based method for NoV using bacterial rRNA depletion as a viral RNA enrichment strategy, and 2)
measured the intra-host genetic diversity of NoV in specimens of patients with acute NoV infection (n = 4) and
in longitudinal specimens of an immunocompromised patient with chronic NoV infection (n = 2).
Results: A single Illumina MiSeq dataset resulted in near full-length genome sequences for 5 out of 6 multiplexed
samples. Experimental depletion of bacterial rRNA in stool RNA provided up to 1.9 % of NoV reads. The intra-host
viral population in patients with acute NoV infection was homogenous and no single nucleotide variants (SNVs)
were detected. In contrast, the NoV population from the immunocompromised patient was highly diverse and
accumulated SNVs over time (51 SNVs in the first sample and 122 SNVs in the second sample collected 4 months
later). The percentages of SNVs causing non-synonymous mutations were 27.5 % and 20.5 % for the first and
second samples, respectively. The majority of non-synonymous mutations occurred, in increasing order of frequency, in
p22, the major capsid (VP1) and minor capsid (VP2) genes.
Conclusions: The results provide data useful for the selection and improvement of NoV RNA enrichment strategies for
NGS. Whole genome analysis using next generation sequencing confirmed that the within-host population of NoV in
an immunocompromised individual with chronic NoV infection was more diverse compared to that in individuals with
acute infection. We also observed an accumulation of non-synonymous mutations at the minor capsid gene that
has not been reported in previous studies and might have a role in NoV adaptation.
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Background
Norovirus (NoV) is recognized as a leading cause of
epidemic and sporadic gastroenteritis around the world
[1]. The viral RNA genome is about 7500 nt long and
contains three ORFs. ORF1 encodes for a polyprotein
that is cleaved into 6 non-structural proteins [2]. ORF2
and ORF3 encode the major (VP1) and minor (VP2)
capsid proteins, respectively. NoVs are classified, based
on VP1 amino acid sequences, into seven genogroups
(GI-GVII) that are further divided into genotypes. To
date, 41 NoV genotypes have been reported of which at
least 29 have been found in humans [3], however, geno-
type GII.4 alone is responsible for over 60 % of all NoV
outbreaks worldwide [4]. New genetic clusters of GII.4,
commonly referred to as GII.4 variants, arise every 2 to
4 years and spread rapidly often causing global pan-
demics [4]. Novel GII.4 variants evolve by antigenic
drift and display changes in VP1 epitopes that can avert
immune responses mounted against previous variants
[5–7]. Homologous recombination is another mechan-
ism responsible for the genetic diversity among NoV
GII.4 and it commonly occurs at the ORF1/ORF2 junc-
tion allowing the virus to exchange structural and non-
structural genes between different GII.4 variants or
even different genotypes [8, 9].
Norovirus acute gastroenteritis is a self-limited illness
typically lasting 2 to 3 days while viral shedding can
range from 13 to 56 days [10]. In immunocompromised
patients, however, NoV shedding is usually prolonged
[11–15] and cases of chronic NoV infection with shed-
ding over 1–2 years have been reported [13, 14, 16].
Due to their long shedding periods and weak immune
responses it has been hypothesized that immunocom-
promised patients with chronic NoV infection might be
reservoirs where new GII.4 variants emerge [12, 17]. In-
deed, ORF2 sequence analysis in these individuals has
shown that the virus can accumulate mutations in VP1
and develop an intra-host NoV population with large
genetic diversity [12, 16, 18–23]. However, it is still un-
clear how other regions of the viral genome evolve in
immunocompromised hosts. More recently, the elderly
and malnourished host have also been proposed as
NoV reservoirs where NoV might accumulate muta-
tions [17] but no studies have yet been performed in
humans to confirm this hypothesis.
The gold standard method to study intra-host NoV
populations involves cloning viral RT-PCR amplicons
into plasmids followed by Sanger sequencing [16, 19, 20,
24], a labour intensive method that requires a relatively
large number of clones to be processed in order to ob-
tain an accurate assessment of the viral diversity. An al-
ternative approach uses next generation sequencing
(NGS) technologies, which process millions of frag-
ments of nucleic acid in a single experiment. NGS is
highly cost-effective in terms of cost per base, however,
since NoV RNA represents a very small fraction of all
stool RNA, as little as 0.01 % [25], the cost per viral
base can be considerable. Fortunately, the efficiency
can be improved by viral RNA enrichment, and strat-
egies previously used for NoV enrichment include
polyA tail selection [26], RT-PCR amplification using
NoV-specific primers [21, 23, 27], VIDISCA [28, 29]
and virus purification [22]. Depletion of rRNA is an-
other possible enrichment strategy [30]. For most cells,
rRNA is the most abundant species of RNA and its re-
moval with commercial kits can substantially increase the
prevalence of non-rRNA [31, 32]. The method poses an
advantage over others in that it maintains the original
representation of the viral population present in the
sample and is less likely to be affected by NoV RNA
fragmentation.
In this study we establish a next generation sequencing-
based method for NoV using bacterial rRNA depletion
as an enrichment strategy for NoV RNA then use the
resulting data to examine the intra-host viral popula-
tion in samples from patients involved in NoV out-
breaks (mostly elderly) and in longitudinal samples
collected from an immunocompromised host with
chronic NoV infection.
Results
Mapping of NoV sequencing reads
The samples included in this study (n = 6) are described
in Table 1. NoV sequences represented 0.01 % to 1.88 %
of all quality-filtered reads and 0.04 % to 8.54 % of the
non-rRNA reads. The non-NoV reads were further char-
acterized and a description is provided under Additional
file 1. The average coverage of the final consensus se-
quences ranged between 11X and 1,603X (Table 2 and
Fig. 1). Five out of six samples yielded near full-length
NoV sequences and called 99.91 to 100 % of the refer-
ence genome. OU3, the sample with the lowest percent-
age of NoV reads and lowest coverage, failed to yield a
complete NoV genome sequence. The percentage of
NoV sequences per sample showed a strong correlation
with the Ct values of the RT-qPCR performed on RNA
stool extracts (Spearman’s rho correlation coefficient:
0.886, P = 0.019, two-tailed). An equally strong correlation
was observed between the percentage of NoV sequences
and viral titer per ng of RNA (Additional file 2). These re-
sults suggest that the poor yield of NoV sequences from
sample OU3 was due to a low abundance of viral RNA ra-
ther than failure of the enrichment method.
In order to validate our NGS method, the NoV con-
sensus sequences of samples OU1 and OU3 obtained
with the MiSeq platform were compared to those ob-
tained using Sanger sequencing. There was a large
concordance between both methods. NoV OU1, which
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achieved high coverage with MiSeq, showed a concord-
ance of almost 100 % between the sequences from both
methods except for one nucleotide. The base mismatch
was located near the 3’end of the genome and was con-
firmed as an error in Sanger sequencing after review of
the Sanger chromatogram and the coverage with MiSeq
at that position (21X). Furthermore, the 5’ and 3’ ends
of the genome could be extended by 9 and 24 nucleo-
tides, respectively, with MiSeq. These nucleotides were
not covered with Sanger because of their close proxim-
ity to the primers used for PCR amplification and
sequencing. The consensus sequence with lowest cover-
age, NoV OU3, showed three mismatches over a total
of 5,081 nt that could be sequenced using Sanger and
MiSeq. The mismatches were identified at 1732 nt,
2167 nt and 2239 nt (positions are given relative to
KU311160) and had, respectively, coverages of 1X, 2X
and 2X and Phred base quality scores of 16, 39 and 39.
All three mismatches occurred at wobble bases result-
ing in synonymous mutations and the last two were lo-
cated in the p22 gene. Since these positions had very
low coverage, it is possible that the mismatches were
created by sequencing errors with MiSeq, however, the
high base quality associated with at least 2 of these
three nucleotides and their relative position in the gen-
ome suggests that they could also represent true SNVs
originally present in the sample.
Detection of single nucleotide polymorphisms
Single nucleotide variants (SNV) were identified to
measure the intra-host genetic population of NoV. In
order to reduce false positives, we only called a SNV if it
was observed at least 5 times and represented a mini-
mum of 2 % of all observations. Using these criteria we
did not detect any SNVs in all acute infection samples
(OU1, OU2, OU3 and OU4). OU3 and OU4 have rela-
tively low coverage (Table 2) limiting the ability to detect
SNVs, but OU1 and OU2 have an average coverage
above 250X and still no SNVs were found. In contrast,
the first sample from the immunocompromised subject
with chronic NoV infection, SP1, had 51 SNVs while
SP2, the second sample collected from the same individ-
ual 4 months later, had 122 SNVs, indicating that the
genetic diversity of NoV in this patient was higher and
also increased over time (Fig. 2). The increased number
of SNVs in SP2 vs. SP1 was confirmed even after con-
trolling for differences in coverage (Additional file 3).
The higher number of SNVs in the SP2 sample was not
due to more sensitive detection, since SP2 had a lower
average coverage than SP1, OU1, and OU2 (Table 2).
The percentages of non-synonymous single nucleotide
variants (nsSNVs) for SP1 and SP2 were 27.5 % and
20.5 %, respectively. There were differences in the distri-
bution of nsSNV across genes between SP1 and SP2. In
SP1, most nsSNVs occurred in p22 (4/14), VP2 (4/14)
Table 1 Samples analyzed by NGS
Sample NoV genotype Sample collection Date Patient description, age group
OU1 GII.4 Sydney 2012 January 2012 Outbreak patient (senior residence), 70-90Y
OU2 GII.4 Sydney 2012 September 2014 Outbreak patient (supportive living), > 70-90Y
OU3 GII.5 November 2013 Outbreak patient (hospital acute care), 30-50Y
OU4 GI.7 November 2012 Outbreak patient (senior residence), 70-90Y
SP1 GII.4 Den Haag 2006b December 2012 Bone marrow transplant patient, < 18Y
SP2 GII.4 Den Haag 2006b April 2013
Table 2 Norovirus reads and coverage per sample
Sample Reads mapping to NoV Percentage of NoV reads Average coverage % of positions calleda Length of consensus
sequence (bp)
Vs. non-rRNA reads Vs. quality filtered reads
OU1 37863 4.01 % 0.51 % 590X 100 % 7532
OU2 88270 5.36 % 1.88 % 1318X 99.55 % 7525
OU3 746 0.04 % 0.01 % 11X 90.59 % N.A.b
OU4 1420 2.43 % 0.02 % 22X N.A. 7657
SP1 102805 8.54 % 1.78 % 1603X 99.91 % 7524
SP2 9589 7.55 % 0.33 % 149X 99.91 % 7535
N.A.: not applicable
aCoverage was calculated compared to KF509946 (OU1), KC631827 (OU2), KJ196277 (OU3), JN899243.1 (OU4) and KC576909 (SP1 and SP2)
bThe alignment of OU3 produced 9 non overlapping contigs of 1744, 281, 518, 394, 434, 106, 119, 487 and 2760 nt long
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and VP1 (3/14) whereas in SP2, the majority of nsSNVs
occurred in VP2 (12/25) and VP1 (9/25) (Table 3). The
enrichment of non-synonymous mutations in VP2, the
P2 domain of VP1 and p22 was statistically significant
(P < 0.05) after controlling for gene/domain size (Table 3)
and is consistent with an increased rate of amino acid
divergence in these proteins. The amino acid residues af-
fected by nsSNVs (summarized in Fig. 3) were mostly
scattered across VP2 (5, 15, 80, 88, 140, 149, 150, 159,
162, 169, 187, 193, 195 and 240) whereas for VP1 all
were located within the P2 domain (294, 340, 341, 344,
373, 374, 377, 378, 380, 403 and 406). Of the 11 muta-
tions occurring at the P2 domain of VP1, two (affecting
amino acid residues 294 and 340) were located at epi-
topes reported to be targeted by antibodies that block
the binding of NoV to human blood group antigens
(surrogates of neutralizing antibodies) [6].
A comparison between the consensus sequences of
SP1 and SP2 revealed differences in 9 positions, of which
2 were synonymous (203 nt and 3851 nt), 6 were non
synonymous (2188 nt, 6095 nt, 6193 nt, 6281 nt, 7141 nt
and 7167 nt; the corresponding amino acid changes are
shown in Fig. 3) and 1 was located at the 3’UTR
(7509 nt). Among the 9 differences between the consen-
sus sequences of SP1 and SP2, 6 were SNVs at SP1 only
(203 nt, 2188 nt, 3851 nt, 6281 nt, 7141 nt and 7167 nt),
1 was a SNV in SP2 only (6095 nt), 1 was a SNV in SP1
and SP2 (6193 nt) and 1 was not a SNV in SP1 nor SP2
(7509 nt). There were a total of 10 SNVs occurring at
the same nucleotide positions of SP1 and SP2 (474 nt,
2303 nt, 4323 nt, 5580 nt, 5706 nt, 6193 nt, 6222 nt,
6803 nt, 7172 nt and 7252 nt; shown with red color in
Fig. 2).
Discussion
In this study we established a method to analyze the
intra-host genetic diversity of NoV in samples from pa-
tients with acute and chronic NoV infection. Our next
generation sequencing-based method coupled to bacter-
ial rRNA depletion as a NoV RNA enrichment strategy
produced between 0.01 % and 1.9 % of NoV reads.




Fig. 1 Coverage per NoV genome position. Number reads (in log scale) that aligned with the corresponding NoV consensus sequence of OU1
(a), OU2 (b), OU3 (c), OU4 (d), SP1 (e) and SP2 (f). Solid and broken lines indicate the start of ORF2 and ORF3, respectively
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samples still contained 64 to 95 % of bacterial rRNA
reads after depletion which differs with a previous
study reporting 1 to 5 % of bacterial rRNA reads after
using the same depletion method with stool RNA [32].
The reasons for the lower rRNA depletion efficiency
observed with our samples could not be identified.
Since the method we used for depletion works with a
library of probes that must first hybridize the bacterial
rRNA for subsequent removal, it is possible that the
hybridization step was affected by sequence incompati-
bility. Also, rRNA depletion was carried out with the
maximum amount of input RNA recommended by the
manufacturer, which could have affected the efficiency
of the method. Based on our data we estimate that if
all 16S and 23S bacterial rRNA could be removed from
stool RNA, NoV sequences would have represented be-
tween 0.04 % and 8.5 % of all NGS reads.
For all but one sample we were able to obtain sufficient
sequence data to retrieve near full-length NoV genome se-
quences. Moreover, even the non-enriched sample (OU4)
provided enough data for de novo assembly of a NoV gen-
ome, AlbertaEI404/2012/CA, which to our knowledge, is
the first near full-length NoV GI.7 genome reported.
Strains of genotype GI.7 were observed with increased
prevalence in Alberta, Canada, between July 2012 and
June 2013 [33] and also among children in Pakistan be-
tween April 2006 and March 2008 [34].
Our analysis included four cases of acute NoV infec-
tion. Two samples from these acute cases, OU1 and
OU2, yielded sufficient coverage to identify SNVs at fre-
quencies ≥ 2 %. However, no NoV SNVs were detected in
these two samples, indicating that the viral population in
typical acute infections is homogeneous. In contrast, we
identified numerous SNVs in an immunocompromised
Fig. 2 Distribution of NoV SNV frequencies across the viral genome. Samples SP1 and SP2 were collected four months apart from an
immunocompromised bone marrow transplant patient with chronic NoV infection. SNV calling was performed using Freebayes. Only SNVs
with frequencies ≥ 2 % and ≥ 5X coverage are reported. Positions with coverage < 10X were excluded from the analysis. SNVs shared in
common between SP1 and SP2 are shown in red
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patient with chronic NoV infection. Interestingly, there was
also an increase of SNV over time (51 SNVs with ≥ 2 % fre-
quency in the first sample and 122 SNVs with ≥ 2 % fre-
quency in the second sample collected 4 months after),
revealing intra-host NoV evolution. As of the date of
writing this manuscript there were two published stud-
ies comparing the intra-host populations of NoV be-
tween immunocompetent and immunocompromised
patients by using NGS data. Both reported similar obser-
vations [21, 22]. Vega et al. found no SNVs throughout
the viral genome (ORF1, ORF2 and ORF3) in an immuno-
competent subject with acute NoV illness but identified
multiple SNVs in three different immunocompromised
bone marrow transplant patients (15, 67 and 235 SNVs
with ≥ 10 % frequency). In an analysis of just the ORF2
and partial ORF3 regions, Bull et al. detected multiple
SNVs in immunocompetent individuals with acute NoV
infection (5 to 8 SNVs with ≥ 2 % frequency). However, an
immunocompromised individual with chronic NoV infec-
tion displayed considerably higher NoV diversity that also
increased over time (48, 59 and 109 SNVs with ≥ 2 % fre-
quency, in three samples collected longitudinally).
Interestingly, about half of the SNVs reported by Bull et
al. were non synonymous (46 to 64 % in immunocompetent
Table 3 Distribution of single-nucleotide variants in NoV by gene. Single nucleotide variants (SNVs) were identified using FreeBayes
in two samples (SP1 and SP2) collected four months apart from an immunocompromised bone marrow transplant patient with
chronic NoV infection. Only those SNVs found at frequencies ≥ 2 % and with 5X coverage are reported. Positions with coverage
< 10X were excluded from the analysis
ORF Gene (other names) Position (nt) SP1 SP2
S NS (P-value*) S NS (P-value*)
1 p48 (NS1-2, N-term, p37) 1–983 6 2 (0.5) 11 2 (0.8)
NTPase (NS3) 984–2081 2 0 (1) 18 1 (1)
p22 (p20, NS4) 2082–2618 3 4 (0.01) 7 1 (0.8)
VPg (NS5) 2619–3014 1 0 (1) 6 0 (1)
3CLpro (NS6) 3015–3560 4 0 (1) 2 0 (1)
RdRp (NS7) 3561–5090 11 1 (0.9) 13 0 (1)
2 VP1 5074–6690 7 3 (0.6) 30 9 (0.06)
S domain 5074–5736 2 0 (1) 9 0 (1)
P1 subdomain 5737–5895, 6325–6690 1 0 (1) 13 0 (1)
P2 subdomain 5896–6324 4 3 (0.03) 8 9 (4x10-6)
3 VP2 6693–7496 3 4 (0.04) 10 12 (1x10-6)
TOTAL 37 14 97 25
*P-values were calculated using binomial distribution and indicate the probability of observing the corresponding number of non-synonymous single nucleotide
variants in the specified region after controlling for gene/domain size
Fig. 3 Distribution per gene of the amino acid residues affected by non-synonymous single nucleotide variants in NoV. Samples SP1 and SP2
were collected four months apart from an immunocompromised bone marrow transplant patient with chronic NoV infection. Residues that
changed between SP1 and SP2 are highlighted in green
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and 34 to 48 % in immunocompromised subjects) whereas
we observed a rate of 21 and 28 % in the immunocom-
promised patient. Our rates are similar to those reported in
another study with bone marrow transplant patients receiv-
ing immunosuppressive drugs (236 non synonymous muta-
tions out of a total of 1082 mutations across 13 samples,
equivalent to an overall rate of 21.8 %) [23]. It could be ar-
gued that Bull et al. achieved higher coverage and therefore
higher resolution of SNVs with PCR, however, at least two
of our samples (one from an outbreak patient and another
from the immunocompromised patient) had average cover-
age levels greater than 1300X, well above 950X, the average
coverage reported by Bull et al. We can only speculate that
the differences between our study and that of Bull et al.
could be due to the processes of quality filtering and trim-
ming of reads as well as the parameters used for SNV call-
ing, which probably were more stringent in our study.
We observed an enrichment of non-synonymous SNVs
in the P2 domain of VP1 which matches the expectation
that the most exposed and possibly the most antigenic
part of the virus bears the highest pressure to diverge. In
fact, the majority of studies analyzing NoV intra-host
genetic diversity have been restricted to identify poten-
tial changes at VP1 [12, 14, 21, 24, 35, 36]. By analyzing
near-full length NoV genomes, we also observed an en-
richment of non-synonymous mutations in VP2, which
suggests that during chronic infection this gene can also
be under pressure to diverge. Although our observations
are based on samples from a single immunocomprom-
ised patient, we believe this is plausible because it agrees
with previous analysis of sequence alignments of mul-
tiple GII.4 strains showing high evolutionary rates for
VP2 [27, 37]. The role of VP2 in the viral life cycle is still
unknown. Only a few copies of VP2 molecules are
present in the final virion (the precise number is yet un-
clear). VP2 appears to bind the interior surface of the
capsid and has been shown to enhance the expression
and half-life of VP1 [38]. Since VP2 is rich in basic resi-
dues and therefore is positively charged, it has also been
suggested that it interacts with the negatively charged
genomic RNA, and possibly plays a role during the en-
capsidation process [38]. The VP2 protein of murine
noroviruses regulates the maturation of antigen present-
ing cells and is an important determinant of NoV pro-
tective immunity [39]. It is interesting to consider that
human NoV VP2 might be an important epitope of host
immune responses.
By analyzing whole NoV genome sequences using
traditional cloning, Chan et al., found accumulation of
mutations at VP1 and VP2 (38 and 15 nt resulting in 9
and 5 amino acid changes, respectively) over a period of
4 months in an immunocompromised patient with
agammaglobulinemia and thymoma [19]. Conversely,
Vega et al. reported that, in comparison to NoV strains
in circulation, NoV mutations in immunocompromised
bone marrow transplant patients occur mostly at ran-
dom positions except for gene p22, which presents a sig-
nificantly large proportion of mutations and positively
selected sites [22]. We speculate that the difference in
results observed in these studies and our study might be
due to temporal changes in the strength and specificity
of host immune responses during chronic infection. This
will be dependent on the type of immunosuppressed
host, the type of exogenous immunosuppression admin-
istered, the time of infection during the patient’s clinical
course and the time of the patient’s immune reconstitu-
tion. Regarding this point, we observed that the distribu-
tion of non synonymous mutations across genes
changed with time which suggests that NoV might face
changes in its evolutionary trajectory during chronic in-
fection as reported for other viruses such as HCV and
HIV [40–42].
Besides whole genome sequencing, NGS methods are
powerful tools for studying viral population dynamics
within a host because of the high sequencing depth
that can be achieved. In addition, samples can be pre-
pared relatively quickly without the need of cloning
into vectors and multiple isolates can be sequenced in
parallel (in our case, six samples were analyzed in one
MiSeq 2x121bp run). The number of samples that can
be sequenced depends on the throughput of the se-
quencing technology and the abundance of the viral
RNA in the sample. Different forms of enrichment can
enhance the later. We demonstrated that bacterial
rRNA depletion is a beneficial treatment that can be
further optimized. Hybrid capture is a promising new
enrichment strategy that remains to be examined in
the future [43].
Conclusions
This study provides data useful for the selection and im-
provement of NoV RNA enrichment strategies for NGS
and is also the first study to look at the intra-host diver-
sity of NoV by analyzing near full length-genomes from
acute cases of NoV infection and in longitudinally col-
lected samples from an immunocompromised patient
with chronic NoV infection. We identified a larger viral
diversity in the immunocompromised patient, which in-
creased over time and we also observed that genes VP2,
p22 and VP1 accumulated the majority of non-
synonymous mutations during chronic infection. Further
studies are needed to observe if the accumulation of mu-
tations at VP2 is consistent across immunocompromised
patients with chronic infection and unveil the role of VP2
and p22 proteins in relationship to host immune re-
sponses. We are currently planning a larger follow-up
study to assess the intra–host genetic diversity of NoV in
solid organ transplant recipients.
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Methods
Patient samples
All stool specimens were collected in Alberta between
2012 and 2014 and stored at -80 °C until analysis. A
total of six stool samples previously genotyped within
our routine program of NoV surveillance in Alberta
were included in this study [33, 44]. The patient’s de-
scription and NoV genotype associated to each sample
are listed in Table 1. Samples OU1, OU2, OU3 and OU4
were collected from outbreak patients with acute NoV
infection. The near full-length norovirus genome for
sample OU1 was determined in a previous study using
Sanger sequencing [9] and was included for comparison
purposes. Samples SP1 and SP2 were collected four
months apart from a pediatric bone marrow transplant
patient who first tested positive for NoV 6 months be-
fore sample SP1 was collected.
RNA extraction
Samples OU1, OU2, OU3, SP1 and SP2 were processed
as follows: 50 to 75 mg of stool were mixed with 20 μL
of proteinase K and 200 μL of lysis buffer from Maga-
zorb®RNA mini-prep kit (Promega, Madison, WI). Nu-
cleic acids were extracted with 1 mL of Trizol® (Life
Technologies, Carlsbad, CA) and according to the
manufacturer’s instructions. The yield of RNA per ex-
traction was estimated using NanoDrop 1000 and the
process was repeated to obtain at least 50ug of RNA
per sample. The extracts were then treated with DNase
(Promega, Madison, WI) and purified by phenol
chloroform extraction and ethanol precipitation. RNA
extracts were eluted through OneStep™ PCR Inhibitor
Removal columns (Zymo Research, Irvine, CA). Bac-
terial rRNA was depleted using Ribo-Zero® bacterial kit
(Epicentre, Madison, WI) according to the manufac-
turer’s instructions using 5 μg of RNA per sample and
purifying by ethanol precipitation as the final step. De-
pletion of bacterial rRNA was performed once per
sample. For comparison purposes, sample OU4 was
processed using our routine enteric virus nucleic acid
extraction method previously described [33, 44] using
Magazorb®RNA mini-prep kit. The nucleic extract was
treated with DNase and purified by phenol chloroform
extraction followed by ethanol precipitation. Sample
OU4 was not depleted of bacterial rRNA. The presence
of norovirus RNA was confirmed in all extracts by RT-
qPCR as previously described [45].
Illumina library preparation and sequencing
Sample libraries were prepared from 1 μg of RNA using
the TruSeq RNA sample preparation kit v2 (Illumina, San
Diego, CA) following the manufacturer’s instructions with
a fragmentation time of 1 min during the “elute-fragment-
prime” step and unique indexed adapters for each sample.
cDNA libraries were quantified with Qubit and the aver-
age fragment size was estimated using the Agilent 2100
Bioanalyzer. A control library of phage X714 was also in-
cluded in each sample. All sample libraries (n = 6) were se-
quenced once on a single Illumina MiSeq run to produce
paired end reads of 250 bp each, resulting in reads of
121 bp each after removing adapters.
Identification, characterization and removal of rRNA reads
Raw sequence reads were quality-trimmed and filtered
with Prinseq-lite, version 0.20.4 [46] using the follow-
ing criteria: the first nucleotide at each end (5’ and 3’)
was trimmed and the following nucleotides were also
trimmed stepwise if their base quality was below 20.
Sequences with an average base quality below 20 or
with more than 90 % of Ns were also removed. A de-
scription of the reads that were filtered is provided in
Additional file 2.
Ribosomal RNA reads were identified and filtered out
with SortmeRNA [47] using the 23S/28S large subunit
(LSU) and 16S/18S small subunit (SSU) rRNA SILVA
119 databases and the 5S and 5.8S rRNA Rfam databases
for all three domains of life (Eukarya, Bacteria and Ar-
chaea). All reads failing to pass filters (i.e. non-rRNA
reads) were maintained as paired-ends reads and used in
downstream analyses the command used for analysis is
described in Additional file 2).
A subset of 150,000 single-end reads with length ≥ 80 nt
and identified as bacterial 23S rRNA, the most predomin-
ant type of rRNA found in all samples, was uploaded in
the SILVAngs data analysis service (https://www.arb-sil-
va.de/ngs/) for identification of operational taxonomic
units (OTUs).
Assembly of NoV genomes
Non-rRNA paired-ends reads of samples OU1, OU2, OU3
and OU4 were mapped using Bowtie, version 2-2.2.5 [48]
to Genbank reference sequences KF509946.2 (genotype
GII.4 Sydney), KC631827.1 (genotype GII.4 2012 Sydney),
KJ196277.1 (genotype GII.5) and JN899243.1 (genotype
GI.7, partial genome), respectively, whereas SP1 and SP2
reads were aligned to KC576909 (genotype GII.4 2006b
Den Haag). The consensus sequence of each sample was
obtained from the alignments (SAM files) using Samtools.
Since no full-length or near full-length genome NoV
GI.7 sequences were available in GenBank, additional
steps were followed for OU4. OU4 reads were assembled
de novo with Velvet version 1.2.10 using several hash
lengths with read category set to ‘short paired’ and in-
cluding the consensus sequence (partial ORF1, complete
ORF2 and ORF3) as a long read (the command used for
this analysis is described in Additional file 2). Norovirus
contigs were identified among all Velvet assemblies with
BLAST [49] using JN899243.1, a genotype GI.9 strain, as
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query sequence. All NoV contigs and the partial consen-
sus sequence were aligned using MEGA 6.0 [50] to ob-
tain the final genome assembly.
The ends of each NoV genome were extended beyond
the reference sequences by using the first and last 15 nt
as query for matches among fastq sequences using the
Unix “grep” command. Matching reads were aligned to
the consensus sequence and any extra nucleotides (5’or
3’ overhangs) were incorporated into the consensus se-
quence. The process was repeated until no more extra
nucleotides were found at either end of the consensus
sequence.
Sample reads were mapped with Bowtie 2 to their re-
spective NoV extended consensus assembly. The final
alignments (SAM files) were used to calculate the
coverage per genome position using BEDTools, version
2.14.3-1 [51].
NoV sequencing using Sanger’s method
The NoV strain from sample OU3 was sequenced using
Sanger’s method to compare results against those ob-
tained with Illumina MiSeq. Nine pairs of primers (de-
scribed in Additional file 2) were designed to retrieve
overlapping PCR amplicons between ~600 to 1100 bp
long, spanning altogether all NoV ORFs. The RT and
PCR reactions were performed as previously described
[9]. PCR products were obtained for six out of nine
pair of primers and were sequenced in both directions.
The assembly of the sequences produced two non-
overlapping contigs: a 3,448 bp sequence containing a
partial ORF1 (incomplete at the 5’ and 3’ ends) and a
1,906 bp sequence spanning ORF2 and ORF3 (incom-
plete at the 5’ and 3’ ends, respectively).
Characterization of non-rRNA, non-NoV sequences
The sequences failing to align with Bowtie 2 to the final
NoV consensus sequence were analyzed with BLAST to
further characterize the major components of stool
RNA. All reads from a single end were queried against
the non-redundant nt database using megablast (standa-
lone version with databases downloaded on July 24,
2015; see parameters of BLAST analysis in Additional
file 2). Results were analyzed with SPSS after removing
duplicates, i.e. if a read had more than one BLAST hit,
then only the hit with the lowest e-value was included in
the analysis. Bacterial hits belonging to the normal hu-
man gut were identified using as reference the microo-
ganisms reported in previous studies [52, 53].
Analysis of single nucleotide variants
Single nucleotide variants (SNVs) were called with Free-
Bayes [54] and visually inspected in Tablet version
1.14.04.10 [55]. The following criteria was used for SNV
calling with FreeBayes: -K (report all alleles passing
filters), –haplotype_length =1 (call haplotypes as 1 nt
long), –m or mapping quality =10 (chance that the read
truly originated elsewhere of 1 in 10), –q or base qual-
ity =20 (chance of a wrong base call of 1 in 100), –F or
alternate fraction =0.02 (call SNVs with frequencies ≥
2 %), –min-coverage =10 (call SNVs for positions with
coverage ≥10X) and –C or min-alternate-count = 5 (call
SNVs with coverage ≥ 5X) (the command used for the
analysis is described in Additional file 2). The choice to
set up the analysis to detect variants with frequencies ≥
2 % was made based on a study reporting that sequen-
cing errors with the MiSeq platform can produce false
variants that are undistinguishable from true low fre-
quencies variants at ≤ 1 % with a 1000X average cover-
age [56]. We also set up the analysis to call SNVs with
a coverage of ≥ 5X based on: 1) a study that eliminated
virtually all false positives by calling variants if counted ≥
10 times independently [57] and 2) the lower coverage per
genome position achieved with our samples compared to
Van den Hoecke et al. [57].
Additional files
Additional file 1: Major components of stool RNA after bacterial rRNA
depletion. This file provides a description of the rRNA and non-NoV-non-
rRNA reads from each sample. (DOCX 1108 kb)
Additional file 2: Various supporting data. This file contains: 1) the data
used to estimate the correlation between percentage of NoVreads and Ct
values, 2) the commands used for NGS analysis, 3) a summary of the
sequences filtered out by Prinseq-lite due to quality control and 4) a de-
scription of the primers designed for sequencing sample OU3 via San-
ger's method. (DOCX 86 kb)
Additional file 3: NoV SNV calling results. This file lists all synonymous
and non-synonymous NoV SNVs detected by FreeBayes in samples SP1,
SP2, and a subset of sequences from SP1 that produced an average NoV
coverage similar to thatobserved in SP2. (XLSX 38 kb)
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